FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138034341> ?p ?o ?g. }

• W3138034341 endingPage "292" @default.
• W3138034341 startingPage "284" @default.
• W3138034341 abstract "The poly-(adenosine diphosphate-ribose) polymerase (PARP) family of proteins participates in numerous functions, most notably the DNA damage response. Cancer vulnerability to DNA damage has led to development of several PARP inhibitors (PARPi). This class of drugs has demonstrated therapeutic efficacy in ovarian, breast, and prostate cancers, but with variable response. Consequently, clinics need to select patients likely to benefit from these targeted therapies. In vivo imaging of ¹⁸F-fluorthanatrace uptake has been shown to correspond to PARP-1 expression in tissue. This study characterized the pharmacokinetics of ¹⁸F-fluorthanatrace and tested kinetic and static models to guide metric selection in future studies assessing ¹⁸F-fluorthanatrace as a biomarker of response to PARPi therapy. <b>Methods:</b> Fourteen prospectively enrolled ovarian cancer patients were injected with ¹⁸F-fluorthanatrace and imaged dynamically for 60 min after injection followed by up to 2 whole-body scans, with venous blood activity and metabolite measurements. SUV_max and SUV_peak were extracted from dynamic images and whole-body scans. Kinetic parameter estimates and SUVs were assessed for correlations with tissue PARP-1 immunofluorescence (<i>n</i> = 7). Simulations of population kinetic parameters enabled estimation of measurement bias and precision in parameter estimates. <b>Results:</b>¹⁸F-fluorthanatrace blood clearance was variable, but labeled metabolite profiles were similar across patients, supporting use of a population parent fraction curve. The total distribution volume from a reversible 2-tissue-compartment model and Logan reference tissue distribution volume ratio (DVR) from the first hour of PET acquisition correlated with tumor PARP-1 expression by immunofluorescence (<i>r</i> = 0.76 and 0.83, respectively; <i>P</i> < 0.05). DVR bias and precision estimates were 6.4% and 29.1%, respectively. SUV_max and SUV_peak acquired from images with midpoints of 57.5, 110 ± 3, and 199 ± 4 min highly correlated with PARP-1 expression (mean ± SD, <i>r</i> ≥ 0.79; <i>P</i> < 0.05). <b>Conclusion:</b> Tumor SUV_max and SUV_peak at 55–60 min after injection and later and DVR from at least 60 min appear to be robust noninvasive measures of PARP-1 binding. ¹⁸F-fluorthanatrace uptake in ovarian cancer was best described by models of reversible binding. However, pharmacokinetic patterns of tracer uptake were somewhat variable, especially at later time points." @default.
• W3138034341 created "2021-03-29" @default.
• W3138034341 creator A5011168502 @default.
• W3138034341 creator A5025647956 @default.
• W3138034341 creator A5033512267 @default.
• W3138034341 creator A5056324339 @default.
• W3138034341 creator A5068379792 @default.
• W3138034341 creator A5074500553 @default.
• W3138034341 date "2021-03-23" @default.
• W3138034341 modified "2023-10-17" @default.
• W3138034341 title "Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia" @default.
• W3138034341 cites W2033670972 @default.
• W3138034341 cites W2050641067 @default.
• W3138034341 cites W2061539036 @default.
• W3138034341 cites W2064255030 @default.
• W3138034341 cites W2065160134 @default.
• W3138034341 cites W2077651427 @default.
• W3138034341 cites W2088342479 @default.
• W3138034341 cites W2102322990 @default.
• W3138034341 cites W2109760090 @default.
• W3138034341 cites W2120897623 @default.
• W3138034341 cites W2136978968 @default.
• W3138034341 cites W2148965526 @default.
• W3138034341 cites W2158485480 @default.
• W3138034341 cites W2169220357 @default.
• W3138034341 cites W2180782489 @default.
• W3138034341 cites W2288033263 @default.
• W3138034341 cites W2345715388 @default.
• W3138034341 cites W2592714610 @default.
• W3138034341 cites W2606865255 @default.
• W3138034341 cites W2614800967 @default.
• W3138034341 cites W2636866226 @default.
• W3138034341 cites W2759735210 @default.
• W3138034341 cites W2887099522 @default.
• W3138034341 cites W2889322279 @default.
• W3138034341 cites W2900997594 @default.
• W3138034341 cites W2914844813 @default.
• W3138034341 cites W2972152268 @default.
• W3138034341 cites W3000447136 @default.
• W3138034341 cites W3011166851 @default.
• W3138034341 cites W3012031705 @default.
• W3138034341 doi "https://doi.org/10.1124/jpet.120.000166" @default.
• W3138034341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33758056" @default.
• W3138034341 hasPublicationYear "2021" @default.
• W3138034341 type Work @default.
• W3138034341 sameAs 3138034341 @default.
• W3138034341 citedByCount "13" @default.
• W3138034341 countsByYear W31380343412021 @default.
• W3138034341 countsByYear W31380343412022 @default.
• W3138034341 countsByYear W31380343412023 @default.
• W3138034341 crossrefType "journal-article" @default.
• W3138034341 hasAuthorship W3138034341A5011168502 @default.
• W3138034341 hasAuthorship W3138034341A5025647956 @default.
• W3138034341 hasAuthorship W3138034341A5033512267 @default.
• W3138034341 hasAuthorship W3138034341A5056324339 @default.
• W3138034341 hasAuthorship W3138034341A5068379792 @default.
• W3138034341 hasAuthorship W3138034341A5074500553 @default.
• W3138034341 hasBestOaLocation W31380343411 @default.
• W3138034341 hasConcept C112705442 @default.
• W3138034341 hasConcept C121608353 @default.
• W3138034341 hasConcept C126322002 @default.
• W3138034341 hasConcept C139254425 @default.
• W3138034341 hasConcept C150903083 @default.
• W3138034341 hasConcept C185592680 @default.
• W3138034341 hasConcept C207001950 @default.
• W3138034341 hasConcept C2777477808 @default.
• W3138034341 hasConcept C2908647359 @default.
• W3138034341 hasConcept C2989005 @default.
• W3138034341 hasConcept C526805850 @default.
• W3138034341 hasConcept C71924100 @default.
• W3138034341 hasConcept C86803240 @default.
• W3138034341 hasConcept C99454951 @default.
• W3138034341 hasConceptScore W3138034341C112705442 @default.
• W3138034341 hasConceptScore W3138034341C121608353 @default.
• W3138034341 hasConceptScore W3138034341C126322002 @default.
• W3138034341 hasConceptScore W3138034341C139254425 @default.
• W3138034341 hasConceptScore W3138034341C150903083 @default.
• W3138034341 hasConceptScore W3138034341C185592680 @default.
• W3138034341 hasConceptScore W3138034341C207001950 @default.
• W3138034341 hasConceptScore W3138034341C2777477808 @default.
• W3138034341 hasConceptScore W3138034341C2908647359 @default.
• W3138034341 hasConceptScore W3138034341C2989005 @default.
• W3138034341 hasConceptScore W3138034341C526805850 @default.
• W3138034341 hasConceptScore W3138034341C71924100 @default.
• W3138034341 hasConceptScore W3138034341C86803240 @default.
• W3138034341 hasConceptScore W3138034341C99454951 @default.
• W3138034341 hasIssue "2" @default.
• W3138034341 hasLocation W31380343411 @default.
• W3138034341 hasOpenAccess W3138034341 @default.
• W3138034341 hasPrimaryLocation W31380343411 @default.
• W3138034341 hasRelatedWork W1966209670 @default.
• W3138034341 hasRelatedWork W1993117784 @default.
• W3138034341 hasRelatedWork W2071248898 @default.
• W3138034341 hasRelatedWork W2083044791 @default.
• W3138034341 hasRelatedWork W2089172952 @default.
• W3138034341 hasRelatedWork W2230266427 @default.
• W3138034341 hasRelatedWork W2417791271 @default.
• W3138034341 hasRelatedWork W2469959921 @default.

• next